PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...

Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...

Discover the power of predictive modeling to forecast future outcomes using regression, neural networks, and more for improved business strategies and risk management.

Stanford Medicine has developed a vision-language artificial intelligence (AI) model that can predict cancer outcomes, such as forecasting melanoma relapses and patient responses to immunotherapy.

The global market for healthcare predictive analytics is expected to grow from $16.7 billion in 2025 and is projected to reach $50.4 billion by the end of 2030, at a compound annu ...

PITTSBURGH – Predictive Oncology Inc. (NASDAQ: NASDAQ:POAI), a company specializing in artificial intelligence (AI)-driven drug discovery with a current market capitalization of $7.93 million, ...

Predictive Oncology, Inc. (NASDAQ:POAI) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were ...

Update (Oct. 1, 00:30 UTC): This article has been updated to include comments from DNA Fund co-founder Chris Miglino. Predictive Oncology (POAI), a biotechnology company specializing in AI-driven ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...